Focus
View

Vir Biotechnology, Inc.

VIR · FY2025

ALIGNED

CEO Package

$7.8M

Pay Ratio

—

Marianne De Backer

Pay reset -15.4% while TSR improved +9.2 pts

ARGENX SE

ARGX · FY2024

MIXED

CEO Package

$0

Pay Ratio

—

Tim Van Hauwermeiren

Awaiting a fuller pay-performance history

Revolution Medicines, Inc.

RVMD · FY2025

MIXED

CEO Package

$14.7M

Pay Ratio

—

Mark A. Goldsmith

Pay and TSR both rose, but not in lockstep

CEOTotal Compensation — All Companies

VIR$7.8MARGX$0KRVMD$14.7M

All values are grant-date fair value as reported in proxy statements.

Key Differences

The fastest way to read this comparison before dropping into the tables.

RVMD carries the largest package at $14.7M, about 1.9x VIR.
ARGX reads mixed, while VIR looks aligned.

Pay Component Breakdown

Latest CEO package mix by company. This stays on the CEO package even if the chart above is showing Top 5 pay.

VIR

Marianne De Backer

$7.8M

base salary12%
stock awards29%
option awards45%
non-equity incentive compensation13%
other compensation1%

ARGX

Tim Van Hauwermeiren

$0

Component-level breakdown is unavailable for this company.

RVMD

Mark A. Goldsmith

$14.7M

base salary6%
stock awards27%
option awards61%
non-equity incentive compensation6%
other compensation0%

Quick Comparison

CompanyCEOLatest YearTotal Comp
Vir Biotechnology, Inc.(VIR)Marianne De Backer2025$7.8M
ARGENX SE(ARGX)N/AN/AN/A
Revolution Medicines, Inc.(RVMD)Mark A. Goldsmith2025$14.7M

Note: All compensation values shown are grant-date fair value as reported in proxy statements. Direct comparisons should account for differences in company size, industry, and compensation structure.

Want to know when these numbers change?

We’ll email you when these companies file a new proxy — so you can see how CEO pay, equity awards, and ratios shift before the next headline.